Quartett C-C031/P-C031 | CD31 (QR034)

品名：PRAME (QR005) | Recombinant monoclonal rabbit antibody

货号：C-P003/P-P003

品牌：Quartett

规格：0.1 ml; 0.5 ml; 1 ml; 3 ml; 7 ml; 15 ml

产品描述

PRAME (PReferentially expressed Antigen in MElanoma) is a tumor-associated antigen that is preferentially expressed on the nuclei of neoplastic melanocytes. The new anti-PRAME antibody is therefore a useful adjunct to testing in situations where antibodies against Hmb-45, Melan A, and SOX10 do not provide sufficient information to distinguish benign from malignant melanocytic lesions. Furthermore, it can also be a valuable marker for assessing the margin of known PRAME-positive melanomas. Sebaceous gland lobules can be used as an internal positive control. Recent publications have shown that diffuse nuclear immunoreactivity for PRAME can be found in 83.2% of primary and 87% of metastatic melanomas. Diffuse PRAME expression is found in all melanoma subtypes, 92.5% in superficial spreading melanomas and 94.4% in acral melanomas. 86.4% of cutaneous melanocytic nevi showed completely negative PRAME staining. PRAME is a cancer-testis antigen (CTA) identified by analyzing the specificity of tumor-reactive T cell clones derived from a patient with metastatic cutaneous melanoma, which showed no expression in normal healthy tissues except the testes, ovaries, placenta, adrenal glands, and endometrium. PRAME is expressed not only by melanomas but also by various non-melanoma neoplasms, including non-small cell lung cancer (NSCLC), breast carcinoma, renal carcinoma, ovarian carcinoma, leukemia, synovial sarcoma, and myxoid liposarcoma. Due to its expression profile, PRAME is a very attractive marker for immunotherapy. Several clinical trials are currently underway attempting to utilize CTAs, including PRAME, for cancer treatment. In addition to its interest as a treatment target for patients with metastatic melanoma, PRAME has been identified as an important biomarker for metastatic risk in Class 1 uveal melanoma.